CD4 and colitis: <b>Conclusions</b>: Our findings demonstrate the role of LXRβ in regulating intestinal CD4<sup>+</sup> T cell senescence to inhibit colitis development, identifying LXRβ as a potential therapeutic target for treating IBD.